Aptamers are oligonucleotide sequences that are capable of recognizing target proteins with an affinity and specificity equal that of antibodies. Aptamers are small single stranded artificial nucleotides with low molecular weight ranging from 5-40k Dalton forming a specific three dimensional structure. Aptamer targets include a variety of small molecules such as amino acids, nucleotides, and antibiotics. They have minor complexity and immunogenicity as compared to antibodies. Aptamers are used in different valuable fields of life sciences like they have been developed as new drug, diagnostic and bio-imaging agent, food inspection and hazardous detection. Aptamers are revolutionizing the healthcare industry by providing the affinity towards a desired target with high selectivity and specificity. This has led research scientists to gain interest in the field of aptamers with increasing support from public-private organizations
The global aptamers market is estimated to be valued at US$ 5,291.8 million in 2022 and is expected to exhibit a CAGR of 18.4% during the forecast period (2022-2030).
Figure 1. Global Aptamers Market Share (%), by Type, 2022
Global Aptamers Market - Driver
Increasing research and development by various universities is expected to drive the global aptamers market over the forecast period. For Instance, in June 2022, a team of researchers from Waseda University announced that they had developed RaptGen. RaptGen, is a variational auto encoder that efficiently discovers new aptamers which are not included in the input SELEX dataset. SELEX dataset is an activated database on selected randomized DNA/RNA sequences addressed to genomic sequence annotation. RaptGen is a novel computational model for aptamer generation.
|Base Year:||2021||Market Size in 2022:||US$ 5,291.8 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||18.4%||2030 Value Projection:||US$ 20,408.6 Mn|
Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, NeoNeuro SAS, Aptagen LLC, Aptus Biotech S.L., AM Biotechnologies, LLC, Base Pair Biotechnologies, Vivonics Inc., CAGE Bio Inc., TAGCyx Biotechnologies Inc., AstraZeneca, GlyTech, Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies, Inc., SomaLogic Operating Co., Inc., Amsbio, and IVERIC bio, Inc.
|Restraints & Challenges:||
Figure 2. Global Aptamers Market Value (US$ Million), by Region, 2022
Global Aptamers Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.
However, the COVID-19 pandemic had a positive impact on the global aptamers market, due to aptamers based therapies.
For instance, in January 2022, according to the data published in National Center for Biotechnology Information, aptamer-based techniques are potentially a good option for treating COVID-19 disease. Aptamers can be used to detect proteins as they are associated with a greater sensitivity of the constructed biosensors because, in a single virus particle, there are significantly more proteins on its surface than copies of the genome inside it. Aptamers are non-immunogenic and bioavailable therapeutic tools that can effectively block the activity of the coronavirus in many aspects including as carriers of therapeutic substances.
Global Aptamers Market: Key Developments
For instance, in March 2021, AstraZeneca, a pharmaceutical and biotechnological company, announced that they had conjugate extended their oligonucleotide drug delivery collaboration with Aptamer Group, a biotechnology company. Under this collaboration, they will research and identify a novel targeting aptamers to deliver drug molecules to the target renal cells
Global Aptamers Market: Restraint
Limitations of aptamers are the major factors that hinder growth of the global aptamers market. For instance, in August 2019, according to the data published in Role of Novel Drug Delivery Vehicles in Nan biomedicine Article, aptamers are well-established therapeutic molecules with high specificity and affinity to their target as comparable to monoclonal antibodies. As aptamers have advantages over antibodies, it also have some limitations that hindered their widespread clinical use as a therapeutic agent. Some of the limitations include renal filtration, serum stability, endocytic escape, and lack of diversity in the aptamer library, nuclease susceptibility and claims of aptamer specificity as well. Many aptamers are prone to quick degradation in biological media due to interactions with biomolecules.
Global Aptamers Market - Key Players
Major players operating in the global aptamers market include Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, NeoNeuro SAS, Aptagen LLC, Aptus Biotech S.L., AM Biotechnologies, LLC, Base Pair Biotechnologies, Vivonics Inc., CAGE Bio Inc., TAGCyx Biotechnologies Inc., AstraZeneca, GlyTech, Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies, Inc., SomaLogic Operating Co., Inc., Amsbio, and IVERIC bio, Inc.
Aptamers are short single-stranded DNA or RNA (ssDNA or ssRNA) molecules that bind to a specific target protein, lipid, or nucleic acid molecules with high specificity. Aptamers can also be conjugated to drugs, and work as drug-delivery systems. For example, aptamers have been conjugated with chemotherapy drugs to turn target and bind to only cancerous cells and leave healthy tissue untouched. Furthermore, factors such as lesser possibility of provoking undesired immune responses, high thermal stability, and cost-efficiency provide are expected to boost demand for aptamers. These are produced through a technique called Systematic Evolution of Ligands by Exponential enrichment (SELEX), which is time-consuming and involves iterative steps. Thus, to overcome this disadvantage, Vivonics Inc., a medical device company, developed and patented a one-step rapid technique named Rapid Isolation of DNA Aptamers (RIDA) for the isolation of high affinity and high selectivity aptamers. Such factors are expected to fuel the adoption of aptamers.
Increasing number of inorganic strategies such as license agreement by the key market players is expected to drive the global aptamers market over the forecast period. For instance, in September 2022, CAGE Bio Inc., a biotechnology company and TAGCyx Biotechnologies Inc., a research based company, announced that they had executed a license agreement for the development of TAGX-0003 for the treatment of Immuno dermatology diseases. Under this agreement, CAGE Bio Inc. will receive a license to develop the drug (TAGX-0003) and TAGCyx Biotechnologies Inc., will receive an upfront payment, sales milestone payments and sales related royalties. TAGX-0003 is a DNA aptamer that possess potent interferon gamma antagonistic activity which penetrates into the skin enabling a non-invasive, efficacious and safe treatment for dermatological diseases.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients